Ocugen CEO and Director Shankar Musunuri sold $589,109 in common stock on September 9, 2026. The transactions were executed under a Rule 10b5-1 trading plan adopted in June 2026.
Musunuri sold 468,727 direct shares at prices ranging from $1.06 to $1.31. He sold an additional 57,264 shares through KVM Holdings, LLC, at prices between $1.11 and $1.14.
The sales occurred as Ocugen shares trade near a 52-week low. The stock recently plummeted after a Phase 2/3 trial for OCU410ST in Stargardt disease showed a negative treatment effect.
Musunuri remains a major shareholder with over 4.48 million shares held directly. He also maintains indirect ownership of more than 1.08 million shares.